



## SUPPLEMENTARY INFORMATION




### Supplementary Figure 1. Influence of sample characteristics in the serum antibodies profile.

Reactivity of IgG (A – C) or IgA (D – E) against the SARS-CoV-2 S protein in serum samples from subjects after receiving the vaccine second dose (T2) of CoronaVac (orange symbols), ChAdOx-1 (yellow symbols), or BNT162b2 (green symbols) vaccines. Data were analyzed with *t* test using the GraphPad Prism V.8 program.



**Supplementary Figure 2. Serum NAb's profile as a function of the participants demographic information.** Serum NAb in samples from subjects after receiving the vaccine second dose (T2) of CoronaVac (orange symbols), ChAdOx-1 (yellow symbols), or BNT162b2 (green symbols) vaccines. NAb were quantified using the cPass™ kit (GenScript). Data were analyzed with *t* test using the GraphPad Prism V.8 program.



**Supplementary Figure 3. Individual grouping according to NAb levels.** Serum NAb levels in samples from all subjects were quantified using the cPass™ kit (GenScript) after receiving the vaccine second dose (T2) and classified as negative (white), low (< 440 U/ml; light purple), medium (440 – 880 U/ml; purple) and high (> 880 U/ml; dark purple). The percentage of individuals presenting low, medium or high NAb levels is shown for those presenting low or high serum IgG (A); and those who were non-reagent or presented low or high IgA (B) levels. Serum antibody levels were classified as non-reagent (under cutoff threshold), low (between the cutoff threshold and 6 SD of the cutoff value) and high (above 6 SD of the cutoff value) for both IgG and IgA.